# Versameb

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/versameb

- Industry: Biotechnology
- Headquarters: Basel, Switzerland
- Website: www.versameb.com
- Total disclosed funding: $6.5M
- Latest round: Seed (Oct 17, 2019)
- Investors on record: 1

## About

Versameb AG is a biotechnology firm focused on developing innovative RNA therapeutics for various medical conditions, particularly targeting rare genetic disorders, cancer, and infectious diseases.Founded in 2017, Versameb AG is based in Basel, Switzerland, and specializes in RNA therapeutics. The company was established by Friedrich Metzger and Norbert Bleich and is led by CEO Klaas Zuideveld. Versameb has completed 3 deals, with its most recent funding round being a Seed round in July 2020, raising CHF 6 million, which accounts for the total amount raised.Versameb specializes in the development of next-generation RNA therapeutics aimed at addressing a variety of medical conditions. Their core product offerings include RNA-based therapies that enhance gene expression and modulation for targeted treatment of diseases. These therapeutics focus on unmet needs in rare genetic disorders, cancer, and infectious diseases. Versameb's innovative solutions cater primarily to biopharmaceutical companies, research institutions, and clinical development partners, with products marketed primarily in North America and Europe, and plans to expand into emerging markets in Asia and Latin America.The revenue model for Versameb is largely based on strategic partnerships and collaborations with biopharmaceutical companies and research institutions. This includes fee-for-service agreements for research and development, along with milestone payments tied to the success of therapeutic candidates in clinical trials. Versameb may also employ revenue-sharing agreements for products that reach commercialization, ensuring a steady income stream as therapies gain market traction. While specific pricing structures are not disclosed, the company's RNA therapeutics are expected to command premium pricing due to their innovative technology and clinical potential.Versameb plans to utilize the CHF 6 million raised in July 2020 to support the development of new RNA therapeutics and expand its market presence. The company aims to launch upcoming products designed to address additional medical conditions, focusing on entering new markets, specifically targeting regions in Asia and Latin America by the end of 2023.

## Funding rounds

- Seed, Oct 17, 2019, $6.5M — Novartis Venture Fund

## Investors

- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Seed